Lorem said it would also order $7 million of Cytori’s products — with aims to market them in China, Hong Kong, Malaysia, Singapore and Australia. The license grants Lorem exclusivity to Cytori’s technology for 30 years.

Cytori has technology that can reconfigure patients’ fat cells, which have been found to have regenerative properties, and uses them to develop breast reconstructive tissue and treatments for heart disease.